LUNG CANCER

Patients with advanced non-small cell lung cancer receiving the combination checkpoint blockade with the PD-L1 inhibitor durvalumab and the anti-CTLA-4 agent tremelimumab had a response rate of 23%, according to phase Ib data from Study 006.

The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) advisory hearing for April 12 to review the new drug application for rociletinib, a treatment for metastatic EGFR T790-mutated non-small cell lung cancer.

Single-dose fosaprepitant dimeglumine (Emend for injection) in combination with antiemetic agents has been approved by the FDA for the preventing

With atezolizumab (MPDL3280A) showing great potential as a treatment for patients with non

Lorraine Pelosof, MD, PhD, assistant professor of Hematology and Oncology, UT Southwestern Medical Center, on the increasing proportion of non-smokers developing non-small cell lung cancer (NSCLC).

Eric Lim, MD, consultant thoracic surgeon, Royal Brompton Hospital, Senior lecturer in thoracic surgery and reader, Imperial College London, discusses the decline in smoking not correlating to the current amount of lung cancer diagnoses.

​Renato G. Martins, MD, MPH, discusses why nivolumab is not ready to move up to being a firstline treatment in non

Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.

A study analysis tackles the ethical debate surrounding the impact of the increasing requirement for research biopsies on the participation of patients with advanced non-small lung cancer in clinical trials.

Marianne Davies, NP, discusses making patients' oncology team their first line of contact should they develop any toxicities related to receiving treatment. Davies says this is important for patients so that the oncology team can assess whether it is an immune-related side effect, or an issue that can be dealt with by their primary care physician.

Researchers have identified a potential new biomarker for non-small cell lung cancer (NSCLC), which may help increase the efficacy of an emerging vaccine based on the MUC-1 antigen.

A team from the Scripps Research Institute and Bristol-Myers Squibb recently collaborated to collectively develop a method for complete chemical synthesis of antroquinonol and to test the biologic activity of the chemically synthesized product. Contrary to previous reports, the study reported minimal in vitro and in vivo antitumor activity of chemically synthesized antroquinonol A.

The success of the immunotherapies pembrolizumab and nivolumab for the treatment of non-small cell lung cancer (NSCLC), and the promising results in NSCLC for the investigational agent atezolizumab, have generated an interest in new combinations with other agents

Although FGFR pathway deregulation has been identified frequently in NSCLC, clinical activity of FGFR inhibitors has been considered disappointing and modest, at best, to date.

A recent study demonstrated that specimens from patients with lung cancer under the age of 50 years appear to be enriched with molecular alterations that are amenable to targeted treatment.

There are no differences in lung cancer incidence or mortality among women of different ethnic groups when adjusted for age, smoking, and other factors, according to an article recently published in the Journal of Clinical Oncology.

Non-small cell lung cancer with mutations in the KRAS gene may be associated with reduced activity of a key endocytic pathway and a mesenchymal phenotype, which may cause metastases.

Rex Chin-Wei Yung, MD, FCCP, discusses the value of teamwork in oncology, specifically lung cancer, and the importance of pulmonologists.

The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

Afatinib utilized as a frontline treatment reduced risk of progression or death by 27%, as compared to gefitinib in patients with EGFR-mutant non-small cell lung cancer. according to a recent phase IIb trial.

The FDA has assigned a breakthrough therapy status to the third-generation EGFR TKI BI-1482694 as a possible treatment for patients with T790M-positive non

The review period for rociletinib for EGFR T790M-positive non-small cell lung cancer (NSCLC) has been extended by the FDA by 3 months. The extension allows ample time to review additional data submitted by the drug's developer, Clovis Oncology.

Alectinib has been granted accelerated approval by the FDA in patients with metastatic ALK-positive non-small cell lung cancer (NSCLC) following progression on crizotinib.

William G. Wierda, MD, PhD, discusses ibrutinib and idelalisib as treatments for non-small cell lung cancer. Wierda says that as it currenlty stands, ibrutinib is approved only for patients with NSCLC with a 17p deletion untreated and idelalisib is only approved for patients with untreated NSCLC.

The FDA has granted a priority review for a supplemental new drug application for crizotinib (Xalkori). The indication is for patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC).